ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes from De Novo Tacrolimus Weight-Based Dosing Compared to Conservative Dosing in Kidney Transplant Recipients.

B. Summers,2 K. Szempruch,1 M. Harris,2 A. Quidley,1 C. Haisch,1 A. Maldonado.1

1Vidant Medical Center/East Carolina University, Greenville, NC
2Duke University Hospital, Durham, NC.

Meeting: 2016 American Transplant Congress

Abstract number: D274

Keywords: FK506, Graft function, HLA antibodies, Kidney transplantation

Session Information

Session Name: Poster Session D: Poster Session II: Kidney Complications-Other

Session Type: Poster Session

Date: Tuesday, June 14, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Purpose: To compare de novo tacrolimus (TAC) weight based dosing (WDG) and conservative dosing (CDG) on incidence and duration of DGF in adult kidney transplant recipients.

Methods: This multicenter study compared 12 months of WDG (N=150, 0.05 mg/kg PO BID) to 12 months of historical CDG (N=161, 1 mg PO BID) from 2013-15. Exclusion criteria: patients with primary non-functioning grafts and those receiving drugs with TAC interactions. Secondary endpoints: time to therapeutic trough (8-10 ng/mL), eGFR, de novo donor specific HLA antibodies (DSA), and incidence of biopsy-proven acute rejection (BPAR) in first 90 days post-transplant.

Results: Demographics were not statistically significant, except for HLA mismatch (4 WDG vs 5 CDG, p=0.04). Majority of recipients were AA (85 WDG vs 105 CDG) and had an average weight of 85 kg. KDPI, CIT, donor type, and pre-op duration of dialysis did not differentiate DGF outcomes. Increasing TAC dose from CDG to WDG did not adversely affect the overall duration of DGF as there was no difference between the two groups; however, incidence of DGF was statistically higher in CDG. Secondary endpoints were not significant with exception of mean time to therapeutic trough. First drawn TAC level >10 ng/mL was found in 22% of patients with DGF, 75% of those were in the WDG.

    Table 1. Secondary Outcomes
   CDG (N=161)  WDG (N=150)  p-value
Time to therapeutic trough, days  15 (+24.7)  6.6 (+5.8)  0.0001 
eGFR (MDRD) at 90 days post-transplant, ml/min/1.73m2  52.9 (+16.9) 51.9 (+19.9)  0.49 
de novo DSA, n 9  5  0.14 
BPAR, n
  Acute cellular rejection
  Antibody-mediated rejection
  Mixed   
14 
  9
  2
  3 
7 
  6 
  0
  1
0.18 

Conclusion: WDG did not have a detrimental impact on duration of DGF or renal function in the first 90 days post-transplant with a significant decrease in time to therapeutic trough, and decreased incidence of de novo DSA and BPAR. Incidence of DGF was higher in the CDG, which may be due to ischemia/reperfusion injury unrelated to the TAC dose.

CITATION INFORMATION: Summers B, Szempruch K, Harris M, Quidley A, Haisch C, Maldonado A. Outcomes from De Novo Tacrolimus Weight-Based Dosing Compared to Conservative Dosing in Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Summers B, Szempruch K, Harris M, Quidley A, Haisch C, Maldonado A. Outcomes from De Novo Tacrolimus Weight-Based Dosing Compared to Conservative Dosing in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-from-de-novo-tacrolimus-weight-based-dosing-compared-to-conservative-dosing-in-kidney-transplant-recipients/. Accessed June 2, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences